Zuventus Healthcare Limited on Tuesday issued a formal clarification dismissing reports and messages circulating about the company’s alleged closure or rebranding, calling them false and misleading. In a statement, the pharmaceutical firm said there has been no closure, suspension, or transfer of its business operations. It also clarified that its field staff remains fully operational across the country and business activities are continuing as usual. The company categorically denied rumours suggesting any disruption to its functioning or future plans.
Zuventus further stated that it has no association or affiliation with any entity named Zorvia Healthcare Limited, adding that such claims are incorrect and have no factual basis. The company said these communications have caused unnecessary confusion among stakeholders. Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its commitment to developing, manufacturing, and marketing high-quality and affordable medicines for patients across India.
Zuventus also said it is exploring appropriate legal remedies to safeguard its goodwill and protect the interests of its stakeholders against the spread of misinformation. The company has a strong presence in branded generics and operates across key therapy areas, including cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals. With a growing field force and a patient-focused approach, Zuventus said it remains focused on improving health outcomes and maintaining long-term trust with doctors, partners, and patients nationwide.